EP Patent

EP0493767A3 — Synergistic combination for treating herpes infections

Assigned to Boehringer Ingelheim Canada Ltd · Expires 1993-03-17 · 33y expired

What this patent protects

Disclosed herein is a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative. The combination is useful for treating herpes infections.

USPTO Abstract

Disclosed herein is a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative. The combination is useful for treating herpes infections.

Drugs covered by this patent

Patent Metadata

Patent number
EP0493767A3
Jurisdiction
EP
Classification
—
Expires
1993-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Canada Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.